Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRE-LDL: Bococizumab for Hyperlipidemia
NCT01968967Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2013
- Primary completion
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of bococizumab in primary hyperlipidemia, mixed dyslipidemia, sponsored by Pfizer. Started Oct 2013; status: completed.
02
Drugs
bococizumab
03
Conditions
primary hyperlipidemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT01968967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01968967.